{"id":49481,"date":"2022-10-11T15:01:43","date_gmt":"2022-10-11T13:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/"},"modified":"2022-10-11T15:01:43","modified_gmt":"2022-10-11T13:01:43","slug":"psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/","title":{"rendered":"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics"},"content":{"rendered":"
\n

PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc.<\/a> (\u201cPsychoGenics\u201d or the \u201cCompany\u201d), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended its drug discovery collaboration with the Company aimed at identifying potential novel drug candidates for the treatment of severe neuropsychiatric disorders.\n<\/p>\n

<\/a><\/p>\n

\nThe initial multi-year agreement, announced in July 2020, allowed Karuna to leverage Psychogenics proprietary screening platforms, which utilize computer vision and machine learning to identify and evaluate new drug candidates to further its pipeline of differentiated neuropsychiatric drugs.\n<\/p>\n

\n\u201cWe are encouraged by the progress of the ongoing research efforts in collaboration with Karuna. This extension in our partnership has the potential to produce the next new generation of neuropsychiatric treatments,\u201d said Emer Leahy, Ph.D., CEO of PsychoGenics. \u201cWe have enjoyed working with the talented Karuna discovery team and look forward to advancing much needed and improved treatments for severely disabling conditions.\u201d\n<\/p>\n

\n\u201cWe are eager to continue our partnership with PsychoGenics, which has made notable progress in advancing our understanding of potential new and novel targets for the treatment of psychiatric conditions,\u201d said Steve Paul, M.D., chief executive officer, president, and chairman of Karuna Therapeutics. \u201cOur partnership is fueled by our shared mission of providing new and meaningful treatment options for patients living with serious mental illness, which would not be possible without novel and collaborative approaches to drug discovery.\u201d\n<\/p>\n

\nAbout PsychoGenics<\/b>\n<\/p>\n

\nPsychoGenics Inc. and its discovery arm, PGI Drug Discovery LLC (collectively known as PsychoGenics), have pioneered the translation of rodent behavioral and physiological responses into robust, high-throughput and high-content phenotyping. PsychoGenics\u2019 drug discovery platforms SmartCube\u00ae, NeuroCube\u00ae, PhenoCube\u00ae and eCube\u2122 have been used in shared-risk partnerships with major pharmaceutical companies, including Sunovion, Roche and Karuna, resulting in the discovery of several novel compounds now in clinical trials or advanced preclinical development. PsychoGenics\u2019 capabilities also include standard behavioral testing, electrophysiology, translational EEG, molecular biology, microdialysis and quantitative immunohistochemistry. In addition, the Company offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington\u2019s disease, autism spectrum disorders, psychosis\/schizophrenia, depression, PTSD, Alzheimer\u2019s disease, Parkinson\u2019s disease, muscular dystrophy, ALS and seizure disorders. For more information, visit PsychoGenics.com<\/a>.\n<\/p>\n

\nAbout Karuna Therapeutics<\/b>\n<\/p>\n

\nKaruna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by serious mental illness. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples\u2019 lives. For more information, please visit www.karunatx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Caitlin Kasunich \/ McKenna Miller
\n
KCSA Strategic Communications
\n
212.896.1241 \/ 949.606.6585
\n
ckasunich@kcsa.com<\/a> \/ mmiller@kcsa.com<\/a>\n<\/p>\n

\nKaruna Media:<\/b>
Lauren Sneider
\n
917-886-0247
\n
lsneider@karunatx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (\u201cPsychoGenics\u201d or the \u201cCompany\u201d), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended its drug discovery collaboration with the Company aimed at identifying potential novel drug candidates for the treatment of severe neuropsychiatric disorders. The initial … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49481","6":"format-standard","7":"category-industry"},"yoast_head":"\nPsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (\u201cPsychoGenics\u201d or the \u201cCompany\u201d), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended its drug discovery collaboration with the Company aimed at identifying potential novel drug candidates for the treatment of severe neuropsychiatric disorders. The initial ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-11T13:01:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221011005199\/en\/1596800\/21\/PGI_Logo_Vector_Tagline_Black_v2_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics\",\"datePublished\":\"2022-10-11T13:01:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/\"},\"wordCount\":496,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005199\\\/en\\\/1596800\\\/21\\\/PGI_Logo_Vector_Tagline_Black_v2_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/\",\"name\":\"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005199\\\/en\\\/1596800\\\/21\\\/PGI_Logo_Vector_Tagline_Black_v2_%281%29.jpg\",\"datePublished\":\"2022-10-11T13:01:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005199\\\/en\\\/1596800\\\/21\\\/PGI_Logo_Vector_Tagline_Black_v2_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005199\\\/en\\\/1596800\\\/21\\\/PGI_Logo_Vector_Tagline_Black_v2_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics - Pharma Trend","og_description":"PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (\u201cPsychoGenics\u201d or the \u201cCompany\u201d), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended its drug discovery collaboration with the Company aimed at identifying potential novel drug candidates for the treatment of severe neuropsychiatric disorders. The initial ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-11T13:01:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221011005199\/en\/1596800\/21\/PGI_Logo_Vector_Tagline_Black_v2_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics","datePublished":"2022-10-11T13:01:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/"},"wordCount":496,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011005199\/en\/1596800\/21\/PGI_Logo_Vector_Tagline_Black_v2_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/","url":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/","name":"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011005199\/en\/1596800\/21\/PGI_Logo_Vector_Tagline_Black_v2_%281%29.jpg","datePublished":"2022-10-11T13:01:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221011005199\/en\/1596800\/21\/PGI_Logo_Vector_Tagline_Black_v2_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221011005199\/en\/1596800\/21\/PGI_Logo_Vector_Tagline_Black_v2_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-extension-of-ongoing-drug-discovery-collaboration-with-karuna-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49481"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49481\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}